Merge Healthcare, Inc. (MRGE) iConnect® Network Signs 19 Contracts in Q1

Merge Healthcare, a provider of clinical systems for the healthcare industry, reports that its iConnect® Network interoperability solution received 19 new contracts in the first quarter of 2014. iConnect Network streamlines the exchange of clinical data to enable healthcare organizations to reduce costs, increase referrals, and meet Meaningful Use 2 (MU2) requirements.

Southern Illinois Healthcare, Merge’s first hospital customer to sign up for the iConnect Network, is a non-profit healthcare system dedicated to promoting the health and well-being of all of the people within the communities they serve.

“We’ve worked with Merge for several years, leveraging their PACS and cardiology solutions, so it was an easy choice to implement Merge’s vendor-neutral archive and iConnect Network for a comprehensive, enterprise-wide imaging strategy,” Dave Holland, Southern Illinois Healthcare’s CIO, stated in the news release. “Despite having a health information exchange in place, we needed a single solution that handles imaging as it becomes more important to healthcare as a whole. With iConnect Network, we’ll meet MU2 requirements for the exchange of images and, most importantly, enable better access to imaging for physicians in order to provide the best care for our patients.”

Among the new contracts are MBB Radiology in Jacksonville, Fla., Radiology Imaging Associates PC in Denver, Colo., Southwest Diagnostic Imaging Center in Dallas, Texas, St. Paul Radiology in St. Paul, Minn., and Washington Radiology Associates PC in Fairfax, Va.

iConnect Network v2.0, the latest version of Merge’s advanced interoperability solution, has been enhanced with several advancements that enables customers to:

•           Deliver radiology reports natively into referring physician electronic health records, without the cost of building custom interfaces through the use of partner networks;

•           Meet MU attestation by quickly indicating when an imaging report was delivered, to whom and when the images were accessed;

•           Simplify system workflows and identify physicians in the network with directory search capabilities; and

•           Access more in depth reporting with links to diagnostic quality images uploaded directly into the provider’s electronic health record.

“The momentum Merge has gained with iConnect Network so far this year reinforces our view that our customers need true interoperable environments to communicate with community physicians outside of their four walls,” said Justin Dearborn, CEO of Merge. “Collaboration and innovation between health systems, providers and radiologists are keys for achieving such an environment. Merge’s ongoing success in creating and launching our advanced imaging and interoperability network is a tribute to our customers diligence as they push ahead to meet new value-based care models and regulatory mandates to enhance the overall patient care experience within their organizations.”

For more information, visit www.merge.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Great Plains Holdings, Inc. (GTPH) Leverages Diverse Business Model for Multiple Revenue Streams

Great Plains Holdings’ business strategy consists of targeting and acquiring controlling interests in small to middle market companies. Great Plains Holdings maintains a diverse business model through two wholly owned subsidiaries for multiple revenue streams and for consistent hard asset growth. These two subsidiaries are Ashland Holdings, LLC, a real estate investment company that acquires, develops, and manages residential and commercial properties; and Lil March, Inc., which engages in the manufacture and sales of the Lil Marc training urinal for young boys in the United States.

At present, Ashland Holdings’ real estate portfolio consists of the following:

•           One 1,400-square-foot corporate office building

•           One 800-square-foot warehouse for LiL Marc’s operations

•           Two adjacent parcels of land, one of which includes a manufactured home that is rented out for additional income

The real estate investment company’s business plan calls for targeting the American Southeast, South, and Midwest for acquiring more real estate holdings. Ashland Holdings also made a foray into oil and gas leases with its completion of a private placement investment in TexStar -Preferred Partner Joint Venture III, LP related to a 150-acre Texas lease in Guadalupe County, Texas. Ashland Holdings will receive income based on net revenue on the lease. It is estimated that around 2.99 million barrels of oil are available for extraction at this lease. Recent oil spot price quotes put the extractable oil reserves at a value of over $300 million. There are about fourteen wells actively producing on the lease at present.

For LiL Marc, Great Plains Holdings has made the LiL Marc training urinal available for purchase through LiLMarc.com as well as through select retail channels. Great Plains Holdings’ management team has rolled out an aggressive marketing plan as for the LiL Marc training urinal, and is building a client list of retailers with brick and mortar stores and other consumer outlets to participate in the broader retail market.

For acquisition targets, Great Plains Holdings looks for investment opportunities primarily within the manufacturing, distribution, consumer products, and real estate spaces. Ideal acquisition targets meet narrowly-tailored criteria, including: having an experienced management team in place; having significant upside growth potential; having low risk for becoming obsolete in their technologies or products; and others factors.

Currently, Great Plains Holdings is looking to acquire private and profitable businesses owned by baby boomers looking to retire. According to Pew Research, since January 2011 roughly 10,000 additional baby boomers reach the threshold of retirement age on a daily basis. That is a trend set to persist until around 2030. A 2007 business owner survey conducted by the U.S. Census Bureau also provides further illumination. The survey found that in 2007, 36.5% of surveyed business owners were 55 years of age or older and 29.6% of surveyed business owners were between 45 and 54 years of age. Great Plains Holdings will expand its portfolio by offering a viable business exit strategy option for these business owners as they prepare themselves for their next stage of life.

For more information about Great Plains Holdings, please visit www.gtph.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine

Today, VistaGen Therapeutics announced that it has received broader intellectual property protection for its stem cell technology platform. The United States Patent and Trademark Office recently issued a notice of allowance (NOA) for U.S. Patent Application 12/836,275, entitled “Cell populations enriched for endoderm cells.” The NOA extends VistaGen Therapeutics’ intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid, and thyroid cells.

When issued, this patent will be complementary to U.S. Patent Nos. 7,763,466, 8,512,957 and 8,143,009, both of which are exclusively licensed by VistaGen Therapeutics from the Ichan School of Medicine at Mount Sinai in New York.

“This patent allowance is another critical step in extending intellectual property protection for our stem cell technology platform. LiverSafe 3D™, one of our core assay systems for drug rescue, in particular stands to benefit greatly from this broader intellectual property protection,” stated Shawn K. Singh, VistaGen’s Chief Executive Officer.

“In addition to expanding the scope of our drug rescue opportunities, this patent allowance and our world-class differentiation expertise put VistaGen in a unique position to pursue potential stem cell research collaborations related to liver biology and drug metabolism assays, as well as pancreatic beta-islet cells for drug and regenerative cell therapy for diabetes,” said Ralph Snodgrass, Ph.D., VistaGen’s President and Chief Scientific Officer.

VistaGen Therapeutics’ reception of the NOA builds on other recent developments that could be promising for the company. VistaGen Therapeutics recently joined the Cardiac Research Safety Consortium, a driving force in public-private research that evaluates the cardiac safety of medical products. The Cardiac Research Safety Consortium draws upon expertise from key stakeholders in the industrial, academic, and governmental sectors for data sharing and expertise. It was launched as a public-private partnership in 2006 through an FDA Critical Path Initiative Memorandum of Understanding with Duke University. With this new membership, VistaGen Therapeutics can benefit from new, key partnerships in the future.

The company’s LiverSafe 3D™ technology is a human liver cell-based biological assay system capable of predicting liver toxicity and metabolism issues in drug candidates that have been stop-gapped for development due to any unexpected liver problems arising during development. This technology is complemented by VistaGen Therapeutics’ other technology, CardioSafe 3D™, another biological assay that is useful in predicting in vivo cardiac effects, both toxic and nontoxic, of promising new drug candidates long before they are tested in humans.

More information about VistaGen Therapeutics, its developments, and its potentially revolutionary innovations for the biotechnological space can be found at www.vistagen.com.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Methes Energies International Ltd. (MEIL) Processors Aligned with Push for Domestic, Clean Energy Source

Biodiesel is the only commercially available fuel that meets the Environmental Protection Agency’s (EPA) definition of “advanced biofuel.” The EPA reports that biodiesel reduces lifecycle greenhouse gases by 86 percent, hydrocarbon emissions by 67 percent, and generates a minimum of $3 billion for the U.S. economy as opposed to spending on foreign oil. And according to Biodiesel.org, the water required to make a latter is 26 times more than is required for biodiesel.

There are numerous environmental and economic advantages that serve as catalysts to the immense growth of the biodiesel market. The U.S. biodiesel industry produced nearly 1.1 billion gallons in 2011 and is pegged to produce nearly 2 billion gallons in 2015, supporting nearly 75 jobs and roughly $7.3 billion in GDP.

The quickening pace of biodiesel demand creates significant opportunity for a variety of biodiesel ventures, from biodiesel supply to biodiesel processing and production to associated software and technology.

Methes Energies International offers a wide range of the spectrum. The company offers a line of products and services to a growing number of biodiesel fuel producers – its biodiesel processors are tailored to each client’s facility and can run on a variety of feedstocks, such as soybean and plant oil, rendered fats, recycled grease, and algae. The company’s fully automated, compact biodiesel processors – the Denami 600 & the Denami 3000 – have emerged as a proven, reliable and cost-effective method to produce quality B100 biodiesel from a variety of feedstock.

With a suite of associated products and services, Methes Energies offers to help clients source their feedstock, market the biodiesel, and track the production process to ensure compliance with EPA regulations. Methes Energies remotely monitors the quality and characteristics of each client’s production, upgrades and services their processors, and advises on adjustments to improve the quality of biodiesel produced.

The renewable energy company also markets and sells biodiesel fuel produced at its showcase production facility in Mississauga, Ontario, Canada, and at its 13 MGY facility in Sombra, Ontario, to customers in the United States and Canada.

Biodiesel is a domestic, sustainable fuel replacement that meets the strict standards of the EPA’s Clean Air Act and reduces dependence on foreign oil. Methes Energies’ technology is a direct response to the need for environmentally sound, strong domestic energy production, and the company has positioned itself with a strong foothold to capitalize on growing demand.

For more information, visit www.methes.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Continental Stock Transfer & Trust Company Offers End-To-End Support for Corporate Actions and Escrows

Besides the short-term and long-term variations in stock price, what investors most often remember are the formal corporate actions undertaken by a company. These actions are the major corporate plays that directly affect shareholders, and the timing and effectiveness with which they are carried out can long determine investor comfort level and responsiveness. For 50 years, Continental Stock Transfer & Trust Company has dedicated itself to public companies, with a special emphasis on smaller to midsize emerging and growth companies, including the support of corporate actions, such as mergers and acquisitions, redemptions, tender and exchange offers, odd lots, forward/reverse splits, rights offers, conversions, subscriptions, and Dutch auctions.

Continental’s corporate actions support is comprehensive and customizable, reflecting the unique needs of growing companies, and covers a range of related services:

Full shareholder servicing

Complete mailing services

End-to-end fulfillment

Powerful, user-friendly online resources and account access

Examination of surrendered securities

Correspondence with the presenter

Tax reporting

Escheatment of aged, unexchanged assets

The company also serves as a valued escrow agent, offering services as a trusted, independent third party for the holding and dispersing of critical assets:

Reviewing the terms of escrow agreement

Ensuring compliance with the escrow agreement

Receiving founder shares in proper transfer order, including Medallion guarantees

Distributing shares

Preparing and providing tax-related reporting

Escrow agent benefits include:

Competitive pricing

Experienced escrow administrators

Lawyer helpful “fill-in-the-blank” forms

Prompt review of escrow agreement

Fast, 24-hr. expedited account opening

All escrow deposits held in segregated bank accounts at JPMorgan Chase Bank

All types of tri-party escrow transactions transactions

Stock and cash escrows

Private placements

Registered offerings

Indemnity escrows

SPAC “Founder” escrow accounts to hold “insider shares” and warrants

Specialized M&A-related escrows

Selling shareholder transactions

Private sale transactions

Crowd funding

Investment services

Examination of “founder”/escrowed shares to ensure transferability, including Medallion guarantees

Income tax reporting

For more information, visit www.ContinentalStock.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Gogo, Inc. (GOGO) Multimedia Platform Enables In-Flight Entertainment, Communication, Internet Access

In 2008, Gogo made its debut as a provider of in-flight connectivity and wireless in-flight digital entertainment solutions. Six years later, more than 2,000 commercial and 6,500 business aircraft are equipped with the company’s exclusive products and services.

Once the aircraft reaches 10,000 feet, passengers with Wi-Fi enabled devices are able to get online and send text messages via the Gogo in-air multimedia platform. In-flight calls are still prohibited by FFA regulations, though passengers can use their wireless device to surf the Internet. Pricing ranges from day passes to monthly subscriptions and flight passes to hourly passes to assure that the customer receives value for the product purchased on each flight.

Gogo’s newest service is Gogo Ground to Orbit (GTO), a proprietary hybrid technology that blends existing satellite technologies with Gogo’s Air to Ground (ATG) network, which offers peak speeds of 60 Mbps or more to aircrafts flying throughout North America. This technology will launch later this year.

Additional products in the company’s technology portfolio include:

•           ATG-4, designed to significantly enhance the existing ATG network and improve per aircraft capacity through the addition of Directional Antenna, Dual Modem, and EV-DO Rev. B technologies;

•           Gogo Satellite products;

•           Gogo Text and Talk products;

•           Gogo Platform, an in-air multimedia platform that gives travelers the information, services, and entertainment; and

•           Gogo Vision, which enables customers to wirelessly stream content such as movies and TV shows from an onboard server to Wi-Fi enabled laptops during flight.

Gogo is headed by company president and CEO Michael Small, a 29-year veteran of the communications industry. Michael previously served as the CEO and director of Centennial Communications Corp.; executive vice president and CFO of 360 Degrees Communications Company; and president of Lynch Corporation, a diversified acquisition-oriented company with operations in telecommunications, manufacturing and transportation services. Michael has an MBA from University of Chicago and holds a Bachelor of Arts from Colgate University.

For more information visit www.gogoair.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

VistaGen Therapeutics, Inc. (VSTA) Stem Cell Expertise Brings New Life to Discarded Drug Candidates

VistaGen Therapeutics is a San Francisco-based biotechnology company that focuses on human stem cell technology for the purposes of drug rescue, predictive toxicology, and drug metabolism screening. The company was founded in 1998 and has spent the last 16 years establishing its reputation as an expert in human pluripotent stem cell (hPSC) technology.

VistaGen Therapeutics’ drug rescue efforts involve combining its hPSC technology with the most up-to-date medicinal chemistry to generate new chemical variants of drug candidates that were abandoned by biotechnology or pharmaceutical companies before the market approval stage.

The drug candidates in which VistaGen is interested include those that were abandoned because of concerns about their effect on the heart and liver. VistaGen believes it can work with these discontinued drug candidates to cost effectively generate new, proprietary variants with reduced toxicity. The company’s end goal is to generate a pipeline of Drug Rescue Variants™ and sell them to biotechnology and pharmaceutical companies so that they can be further developed, approved, and sold commercially.

VistaGen Therapeutics is accomplishing its goals through the use of its hPSC technology platform, called Human Clinical Trials in a Test Tube™. The technology allows VistaGen to assess the Drug Rescue Variants’ heart and liver safety profiles.

Though there are other technologies like this on the market, Human Clinical Trials in a Test Tube™ is unique because it allows VistaGen to perform this task with greater speed and precision than conventional testing technology. Often times, companies spend decades and millions of dollars in drug candidates that only result in failure. VistaGen’s model is designed to leverage third-party investments, speed up the testing process, and recycle candidates that may have only been a few steps shy of being successful.

VistaGen’s research initiatives extend beyond its laboratories. In April 2014, the company announced that it became a member of the Cardiac Safety Research Consortium, an organization that supports research into the evaluation of cardiac safety of medical products. VistaGen is committed to staying at the cutting edge of cardiac safety, given that it is the lynchpin for the success of its proprietary drug candidates.

For more information, please visit www.vistagen.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Methes Energies International Ltd. (MEIL) Extensive Know-How Produces Client Success

Methes Energies is a biodiesel producer with a portfolio of products and services that aids companies in the biodiesel production industry. The company delivers a myriad of solutions for a wide range of challenges in the biodiesel industry. Methes Energies offers help with sourcing companies’ feedstock, marketing their biodiesel, supporting companies through the chemistry challenges of making on-spec biodiesel, and staying compliant with RSF2 and EPA regulations throughout every step of the production process. Companies that work with Methes Energies are provided with peace of mind as the company’s aim is to help businesses succeed by addressing the challenges, requirements, and compliance issues all companies in the biodiesel space face throughout the production process.

Methes Energies is able to provide its consultation-style services through the work of a committed staff with over ten years of daily hands-on experience. Simply put, the company helps its customers by bringing clarity to the challenges biodiesel companies regularly encounter. Their expertise assists other companies, as well as their own, in maintaining the high level of quality and success on which it built its name. MEIL’s team of consultants and strategic partners offers consulting, operational and troubleshooting services, covering every aspect and phase of a biodiesel project, as well as biodiesel production. Meyhes also offer practical solutions based on real-life experiences. From plant design and management, MEIL’s team assists in identifying the expansion solution tailored to its client’s current facility, or additional equipment requirements, such as a pre-treatment and post-treatment system.

In addition to helping businesses in the biodiesel sector succeed, Methes Energies offers a top-notch biodiesel processor system that is unique by way of being fully automated and featuring a continuous flow that can run on a variety of feedstock. The company also sells the biodiesel fuel it produces at its production center in Mississauga, Ontario, Canada.

As of March 2014, Methes Energies has received its first manufacturing order from Antilla Energy VBA to produce a Denami 600, which will be delivered to Aruba upon completion. The company believes that this order is just a glimpse of the achievable success it anticipates going forward. The company looks forward to receiving many more orders of this nature as it executes its well-conceived business plan.

For more information, please visit www.methes.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Busy IPO Market Making Up for Lost Time

Last week was a huge one for initial public offerings, as companies who had delayed the big move due to the country’s financial crisis now try to make up for lost time. Six of the companies on top of the IPO list are shown below.

Zoe’s Kitchen, Inc. (ZOES) – Texas based Zoe’s Kitchen is a growing restaurant chain cashing in on the burgeoning demand for healthy non-processed foods made from scratch. The company currently has over 110 locations in 15 states, and offers Mediterranean-inspired dishes. The company motto is: “If it wasn’t food 100 years ago, it isn’t food today.” Zoe’s announced its IPO of 5,833,333 shares of common stock at a price to the public of $15.00 per share, with shares beginning trade Friday on the NYSE under the ticker symbol ZOES.

Lombard Medical Technologies (EVAR) – Lombard develops and produces endovascular stent-grafts to repair aortic aneurysms. Aorfix, the company’s lead product, is currently the only abdominal aortic aneurysm stent-graft approved by the FDA for the treatment of such aneurysm’s with angulation of up to 90° at the neck of the aneurysm. Abdominal aortic aneurysms are a major cause of death in the U.S. The company initiated its IPO Friday, offering 3.6 million shares priced at $15-$18 per share, listing on the Nasdaq exchange under the ticker symbol EVAR.

Aldeyra Therapeutics (ALDX) – Aldeyra is a biotechnology company focused on developing drugs to eliminate free aldehydes, naturally occurring inflammation-inducing chemicals that are factors in a number of diseases. The company says that they are unaware of any associated FDA approved therapy like this. Aldeyra’s Friday IPO covered 2.2 million shares, priced at $10-$11, on the Nasdaq exchange, under the ticker symbol ALDX.

Paycom Software (PAYC) – Oklahoma City based Paycom Software provides cloud software for payroll, human resources, and other human capital management requirements. The company’s offerings are designed to help companies streamline their employment processes and eliminate redundant data entry. Paycom’s Friday IPO was for 6.6 million shares, priced between $18 and $20, on the NYSE, under the ticker symbol PAYC.

Enable Midstream (ENBL) – A publicly traded limited partnership, Enable Midstream owns, develops, and operates strategically located natural gas and crude oil infrastructure assets in major producing basins. Using these assets, the company provides comprehensive services to gather, process, transport, and store primarily natural gas in the south central U.S. The company’s IPO offered 25 million common units representing limited partner interests at a public price of $20.00 per common unit, on the NYSE, under the ticker symbol ENBL.

Phibro Animal Health Corp. (PAHC) – New Jersey based Phibro is one of the world’s leading animal health companies, focused on helping to meet the growing demand for animal protein. They provide livestock producers with a broad range of products and solutions to help maintain and enhance the health and productivity of animals. Stock covered includes beef and dairy cattle, poultry, swine, and even aquaculture. The company’s IPO offered 11,765,000 shares of its Class A Common Stock, with an estimated price range for the initial public offering of $16 to $18 per share, on the Nasdaq, under the ticker symbol PAHC.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.htmlBusy IPO Market Making Up for Lost Time

Last week was a huge one for initial public offerings, as companies who had delayed the big move due to the country’s financial crisis now try to make up for lost time. Six of the companies on top of the IPO list are shown below.

Zoe’s Kitchen, Inc. (ZOES) – Texas based Zoe’s Kitchen is a growing restaurant chain cashing in on the burgeoning demand for healthy non-processed foods made from scratch. The company currently has over 110 locations in 15 states, and offers Mediterranean-inspired dishes. The company motto is: “If it wasn’t food 100 years ago, it isn’t food today.” Zoe’s announced its IPO of 5,833,333 shares of common stock at a price to the public of $15.00 per share, with shares beginning trade Friday on the NYSE under the ticker symbol ZOES.

Lombard Medical Technologies (EVAR) – Lombard develops and produces endovascular stent-grafts to repair aortic aneurysms. Aorfix, the company’s lead product, is currently the only abdominal aortic aneurysm stent-graft approved by the FDA for the treatment of such aneurysm’s with angulation of up to 90° at the neck of the aneurysm. Abdominal aortic aneurysms are a major cause of death in the U.S. The company initiated its IPO Friday, offering 3.6 million shares priced at $15-$18 per share, listing on the Nasdaq exchange under the ticker symbol EVAR.

Aldeyra Therapeutics (ALDX) – Aldeyra is a biotechnology company focused on developing drugs to eliminate free aldehydes, naturally occurring inflammation-inducing chemicals that are factors in a number of diseases. The company says that they are unaware of any associated FDA approved therapy like this. Aldeyra’s Friday IPO covered 2.2 million shares, priced at $10-$11, on the Nasdaq exchange, under the ticker symbol ALDX.

Paycom Software (PAYC) – Oklahoma City based Paycom Software provides cloud software for payroll, human resources, and other human capital management requirements. The company’s offerings are designed to help companies streamline their employment processes and eliminate redundant data entry. Paycom’s Friday IPO was for 6.6 million shares, priced between $18 and $20, on the NYSE, under the ticker symbol PAYC.

Enable Midstream (ENBL) – A publicly traded limited partnership, Enable Midstream owns, develops, and operates strategically located natural gas and crude oil infrastructure assets in major producing basins. Using these assets, the company provides comprehensive services to gather, process, transport, and store primarily natural gas in the south central U.S. The company’s IPO offered 25 million common units representing limited partner interests at a public price of $20.00 per common unit, on the NYSE, under the ticker symbol ENBL.

Phibro Animal Health Corp. (PAHC) – New Jersey based Phibro is one of the world’s leading animal health companies, focused on helping to meet the growing demand for animal protein. They provide livestock producers with a broad range of products and solutions to help maintain and enhance the health and productivity of animals. Stock covered includes beef and dairy cattle, poultry, swine, and even aquaculture. The company’s IPO offered 11,765,000 shares of its Class A Common Stock, with an estimated price range for the initial public offering of $16 to $18 per share, on the Nasdaq, under the ticker symbol PAHC.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.htmlBusy IPO Market Making Up for Lost Time

Last week was a huge one for initial public offerings, as companies who had delayed the big move due to the country’s financial crisis now try to make up for lost time. Six of the companies on top of the IPO list are shown below.

Zoe’s Kitchen, Inc. (ZOES) – Texas based Zoe’s Kitchen is a growing restaurant chain cashing in on the burgeoning demand for healthy non-processed foods made from scratch. The company currently has over 110 locations in 15 states, and offers Mediterranean-inspired dishes. The company motto is: “If it wasn’t food 100 years ago, it isn’t food today.” Zoe’s announced its IPO of 5,833,333 shares of common stock at a price to the public of $15.00 per share, with shares beginning trade Friday on the NYSE under the ticker symbol ZOES.

Lombard Medical Technologies (EVAR) – Lombard develops and produces endovascular stent-grafts to repair aortic aneurysms. Aorfix, the company’s lead product, is currently the only abdominal aortic aneurysm stent-graft approved by the FDA for the treatment of such aneurysm’s with angulation of up to 90° at the neck of the aneurysm. Abdominal aortic aneurysms are a major cause of death in the U.S. The company initiated its IPO Friday, offering 3.6 million shares priced at $15-$18 per share, listing on the Nasdaq exchange under the ticker symbol EVAR.

Aldeyra Therapeutics (ALDX) – Aldeyra is a biotechnology company focused on developing drugs to eliminate free aldehydes, naturally occurring inflammation-inducing chemicals that are factors in a number of diseases. The company says that they are unaware of any associated FDA approved therapy like this. Aldeyra’s Friday IPO covered 2.2 million shares, priced at $10-$11, on the Nasdaq exchange, under the ticker symbol ALDX.

Paycom Software (PAYC) – Oklahoma City based Paycom Software provides cloud software for payroll, human resources, and other human capital management requirements. The company’s offerings are designed to help companies streamline their employment processes and eliminate redundant data entry. Paycom’s Friday IPO was for 6.6 million shares, priced between $18 and $20, on the NYSE, under the ticker symbol PAYC.

Enable Midstream (ENBL) – A publicly traded limited partnership, Enable Midstream owns, develops, and operates strategically located natural gas and crude oil infrastructure assets in major producing basins. Using these assets, the company provides comprehensive services to gather, process, transport, and store primarily natural gas in the south central U.S. The company’s IPO offered 25 million common units representing limited partner interests at a public price of $20.00 per common unit, on the NYSE, under the ticker symbol ENBL.

Phibro Animal Health Corp. (PAHC) – New Jersey based Phibro is one of the world’s leading animal health companies, focused on helping to meet the growing demand for animal protein. They provide livestock producers with a broad range of products and solutions to help maintain and enhance the health and productivity of animals. Stock covered includes beef and dairy cattle, poultry, swine, and even aquaculture. The company’s IPO offered 11,765,000 shares of its Class A Common Stock, with an estimated price range for the initial public offering of $16 to $18 per share, on the Nasdaq, under the ticker symbol PAHC.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

VistaGen Therapeutics, Inc. (VSTA) Commercial Drug Rescue Potential Underwritten by Stem Cell Bioassay’s Cardiac Drug Safety Benchmarking

VistaGen’s human pluripotent stem cell (hPSC) based approach to salvaging the massive outlays that are otherwise eaten when a once-promising drug candidate is dropped due to unexpected heart or liver toxicity complications (or preemptively preventing such losses), using their proprietary Human Clinical Trials in a Test Tube™ platform to accurately model the effects and develop safer Drug Rescue Variants™, also happens to be extremely useful for modeling non-toxic effects and thus represents a framework technology for drug development unlike anything which has come before it. The core component of this platform, an in-vitro bioassay system that utilizes functional/mature human heart cells derived from hPSCs to create three dimensional cardiac tissues, known as CardioSafe 3D™, is designed to be vastly more precise and expedient than extant surrogate safety models.

VistaGen recently reported (Apr 10) some big news in this area that will no doubt lead to key partnerings in future, as the company has become a member of the renowned public-private medical product cardiac safety research organization, the Cardiac Safety Research Consortium (CSRC), which was created back in 2006 via the FDA’s Critical Path Initiative MoU with Duke University. Since inception, the CSRC has come to be known as a driving force in public health and cardiac safety among the wide range of academic, governmental, and industrial stakeholders in the biopharma space which it engages in the support of these ends.

President of VSTA and the company’s CSO, Ralph Snodgrass, Ph.D., underscored the significance of mounting cardiac safety concerns associated with new drug candidates and the importance of identifying complications prior to human studies, further emphasizing that these concerns are the very internal mechanism which drives VSTA itself. Snodgrass also pointed to the key area of proarrhythmia safety, a serious and not infrequent complication in antiarrhythmic drugs where they actually provoke new arrhythmia (or a marked spike in the frequency of a preexisting arrhythmia), as being a primary target. Professor of Medicine at Duke and CSRC Co-Chair, Mitchell Krucoff, MD, FACC, hailed the start of a long and productive relationship with VSTA, noting the company’s commitment to proactive cardiac safety and how their membership strengthens the CSRC as well.

VSTA has winning technology here, with their ability to create a 3D bioassay that can be used to rapidly assess and benchmark new drugs, offering levels of detail and accuracy that make existing animal models or mere in-vitro cell culture approaches look like the antiquated technologies that they really are. The long-term potential for VSTA to prove up Drug Rescue Variants is enhanced by being able to make strategic connections through the CSRC membership and this relationship will help throw a spotlight on the compelling advantages of the company’s technology for predictive toxicology and drug metabolism assays, in addition to drug rescue.

Alongside CardioSafe 3D™, VSTA has developed a second major Human Clinical Trials in a Test Tube component, LiverSafe 3D™, designed to test drug-drug interactions and provide the same kind of over-the-horizon radar system for liver toxicology. In light of prior CardioSafe 3D™ developments regarding its use as a clinically predictive system for assessing cardiac toxicity in anti-cancer drugs, especially the revolutionary new small molecule kinase inhibitors which have drawn criticism (despite other benefits) for causing cardiac events not detected during drug development, this latest news about the CSRC membership is very bullish for VSTA and investors should keep an eye on the company as the broader biotech sector trims.

More info on this pioneering biotech developer is available at www.VistaGen.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Paycom Software, Inc. (PAYC) Provides Unique Set of Streamlined Human Capital Management Services

Paycom Software is an Oklahoma City-based provider of cloud-based software for human capital management, such as payroll, talent acquisition, payroll, and human resources. The company’s technology encompasses a suite of products within a single application with payroll operating as its system of record.

Once a candidate’s information is entered via online application, Paycom clients can run tax credit checks and background checks as well as the “on-boarding process” without re-entering the candidate’s information. Through employee self-service, new hires can complete their W-4s and I-9s, which can be automatically checked with E-Verify®. Employees can also use the self-service portal for a variety of tasks, such as to clock in and out, submit online timesheets, check their paid-time-off accruals, and make time off requests. The employees can also access pay vouchers, submit expenses, enroll in benefits, and access performance reviews.

The design of the technology is to help businesses streamline their employment processes and eliminate redundant data entry through a single database. Paycom’s client base includes businesses engaged in manufacturing, franchise, medicine, restaurants, education, non-profit, distribution, grocers, dealerships, and more.

Business owners benefit from automatically populated payroll that includes benefit deductions, expense reimbursement amounts, and any other approved changes made in the system, such as changes to pay scale or position or status changes. Additionally, when a qualifying event such as employee termination is entered into the system, the required COBRA action is triggered automatically to keep the business in compliance.

To foster continued growth, Paycom today launched its initial public offering (IPO) for inclusion to the New York Stock Exchange. The company plans to raise $100 million through the sale of 6.6 million shares priced between $18 and $20 a piece.

For more information, visit www.paycom.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Lombard Medical Technologies (EVAR) Flagship Product Meets Unmet Need in Treatment of Abdominal Aortic Aneurysms

Lombard Medical Technologies is a medical technology company specializing in developing, manufacturing, and marketing endovascular stent-grafts to repair aortic aneurysms. The company’s lead product, Aorfix™, is the only abdominal aortic aneurysm (AAA) stent-graft approved by the U.S. FDA for the treatment of AAAs with angulation of up to 90°at the neck of the aneurysm.

AAAs are the 13th leading cause of death in the United States and the 10th leading cause of death in U.S. men aged 65 years and older. Current treatment options involve invasive open surgical repair, or less invasive endovascular aortic repair (EVAR). Medtech Ventures pegs the global EVAR market at approximately $1.4 billion in 2013, with the U.S. market estimated at approximately $680 million.

“Tortuous anatomy” affects roughly 20-30% of patients suffering from AAA; Aorfix is specifically targeted at this segment of the market. In contrast to rigid design of competitor products, Aorfix has a coil design that provides flexibility for use in patients with tortuous anatomies that cannot be satisfactorily treated with other licensed stent grafts. In addition, competitor products are typically only licensed for use in aneurysms with proximal neck angulations of up to 60°. There are no EVAR devices other than Aorfix approved by the FDA to treat AAAs with high angle neck anatomy of greater than 60°.

Lombard Medical Technologies formally launched the U.S. roll-out of Aorfix in November 2013, and anticipates receiving regulatory approval to market Aorfix in Japan in 2014.

The company is also developing a stent-graft system to treat thoracic aortic aneurysms (TAAs), which are aneurysms similar to AAAs but located in the thoracic aorta. According to Medtech Ventures, the worldwide TAA market was valued at approximately $380 million in 2013, and is estimated to grow to more than $480 million by 2018.

To achieve its goal of becoming a profitable company within three years, Lombard Medical Technologies has established four key business objectives: increase commercial revenues in Europe principally through the expansion of its sales and marketing infrastructure; obtain regulatory approval for Aorfix in the U.S. and to launch the product in the U.S. with a direct sales force; expand the size range for Aorfix and make enhancements to its delivery system to ensure the product remains competitive in terms of profile and ease of use; and make operational efficiency improvements to increase capacity and improve gross margins.

Lombard Medical Technologies is listed on the London Stock Exchange under the ticker symbol “LMT.” The company today initiated its initial public offering (IPO) for listing on the Nasdaq exchange, offering 3.6 million shares priced at $15-$18 per share for a total offer amount of $75.2 million.

For more information, visit www.lombardmedical.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Aldeyra Therapeutics (ALDX) Develops “Traps” to Capture Disease-Causing Toxins

Aldeyra Therapeutics is a biotechnology company developing a novel drug platform of drug candidates designed to trap free aldehydes, which are naturally occurring chemical species considered to be inflammatory-inducing, toxic links to many diseases, including autoimmune, inflammatory, and neurological diseases.

Aldeyra has developed a suite of “traps” designed to capture and eliminate free aldehydes, which ideally would allow for the treatment and prevention of disease, as well as slowed progression of chronic disease. In animal testing, the company’s lead compound, NS2, was generally safe and well-tolerated topically and systemically. In a phase 1evaluation trial in human subjects, NS2 was safe and well-tolerated when administered as an eye drop.

In 2014, the company plans to initiate the following studies for NS2: phase II trials in discoid lupus, acute anterior uveitis, and ocular rosacea; a phase III trial in the rare Sjogren-Larsson syndrome; and a phase I study to test the safety of an oral formulation of the candidate. For rare diseases, Aldeyra intends to pursue orphan drug designation of its platform from the United States Food and Drug Administration (FDA).

To raise capital to fund its clinical trials and to develop additional aldehyde traps for the treatment of other diseases, Aldeyra today made its market debut on the Nasdaq exchange with a $31.3 million initial public offering (IPO) of 2.2 million shares priced at $10-$11 a piece.

“We believe there is significant unmet medical need for the therapies we intend to develop. We are not aware of any therapy that has been approved by the United States Food and Drug Administration, or the FDA, for SLS or ocular rosacea with meibomian gland dysfunction. … We believe that NS2 has the potential to be the first in class of aldehyde traps for the diseases described above and potentially for inflammatory and other diseases generally. None of our products have been approved for sale in the United States or elsewhere,” the company stated, as reported by Nasdaq.com.

For more information visit http://www.aldeyra.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Why Rosetta Genomics, Ltd. (ROSG) is the Leader in MicroRNA-Based Cancer Testing Services

Rosetta Genomics has developed a suite of microRNA-based diagnostics that were discovered through the company’s proprietary microRNAs and platform technologies. These technologies have made considerable headway in the medical field, demonstrating how microRNAs have the potential to accurately diagnose and classify cancer, as well as to identify the origin of metastases, or where the cancer originated in the body.

Founded in 2000, Rosetta can be credited with building the field of microRNAs, and was one of the first to demonstrate that serum microRNAs can be novel biomarkers, which are molecular “flags” indicative of a biological state or condition. Thus far, the company has discovered more than 300 biologically validated novel human microRNAs.

This discovery is significant, considering that microRNAs have already demonstrated potential to revolutionize cancer diagnostics. The company has also identified microRNAs’ central role to a host of other conditions, including autoimmune and inflammatory diseases, cardiovascular diseases, diabetes and obesity, infectious diseases, and neurological disorders.

Rosetta’s technologies are packed into an intellectual property portfolio that currently consists of 33 issued patents, two allowed patents, and 46 patent applications. Building on this strong patent position and proprietary platform technologies, Rosetta is working to apply these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools.

Rosetta currently has four revenue-generating microRNA-based diagnostic tests targeting: cancer origin; lung cancer; kidney cancer; and mesothelioma, a form of cancer most commonly found in the chest and abdomen, generally connected to asbestos exposure.

•           The Rosetta Cancer Origin Test™ accurately identifies the primary tumor type in primary and metastatic cancer by measuring the expression levels of 64 microRNAs, which are then processed through the company’s proprietary algorithm. The test results can accurately identify the origin of the patients’ tumor for 49 cancer origins with 85% sensitivity and 99% specificity. By determining cancer origin, clinicians can better diagnose patients and determine optimal treatment options.

•           The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer: squamous Non-Small Cell Lung Cancer (NSCLC), non-squamous NSCLC, Small Cell Lung Cancer or carcinoid. The test is based on the expression level of eight microRNAs extracted via cytological procedures such as fine-needle aspiration (FNA), bronchial brushing and washing, and biopsy sample.

•           The Rosetta Kidney Cancer Test™ uses 24 microRNAs to accurately classify the four most common kidney tumors: Clear cell RCC, Papillary RCC, Chromophobe RCC, and benign Oncocytoma. A validation set of 201 independent samples was classified using the test and analyzed blindly. The test produced results for 92% of the samples with an accuracy of 95%.

•           The Rosetta Mesothelioma Test™ leverages the high specificity of microRNAs as biomarkers to differentiate mesothelioma, a malignant tumor connected to asbestos exposure, from carcinomas in the lung and pleura, a medically and legally important differential diagnosis. Distinguishing between the two conditions is vital, and allows for specific and treatment regimens for each condition. Currently there is no other single diagnostic test that is conclusive for this differentiation.

Cancer obviously isn’t constrained by geological boundaries, and to capture its portion of the global diagnostics market Rosetta offers its four commercial-stage oncology tests in multiple countries around the world; implemented a global comprehensive sales and marketing effort for its cancer origin test; obtained Medicare and private pay coverage for the origin test; initiated a master service provider agreement with a global biopharmaceutical company; and plans to execute collaboration deals with additional pharma/biotech and Dx companies.

In 2013, Rosetta raised more than $3 million in financing and at year-end reported more than $20 million in cash, which the company says is enough to fund operations well into 2015. Furthermore, the company has no debt.

These factors position Rosetta with room to leverage microRNAs as stable, sensitive, and specific markers, and to advance and develop multiple diagnostic programs in cancer and for various other indications to enable accurate diagnosis and targeted treatment. The company’s current product pipeline consists of programs in various stages of development and/or marketing: thyroid neoplasia, the company’s lead product with launch expected in 205; bladder, ovarian and breast cancers; heart failure, kidney rejection; Alzheimer’s disease; and cytomegalovirus (CMV) therapeutics.

For more information visit www.rosettagenomics.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html